Industry
Biotechnology
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Avi Kapoor
August 21, 2024 | 9:47 am
Portfolio Pulse from Benzinga Newsdesk
August 14, 2024 | 12:05 pm
Portfolio Pulse from Benzinga Newsdesk
August 14, 2024 | 12:02 pm
Portfolio Pulse from Benzinga Newsdesk
July 01, 2024 | 11:11 am
Portfolio Pulse from Benzinga Newsdesk
June 14, 2024 | 11:17 am
Portfolio Pulse from Benzinga Newsdesk
May 31, 2024 | 11:19 am
Portfolio Pulse from Benzinga Newsdesk
May 31, 2024 | 11:14 am
Portfolio Pulse from Benzinga Newsdesk
May 24, 2024 | 4:50 pm
Portfolio Pulse from Benzinga Newsdesk
May 14, 2024 | 4:35 pm
Portfolio Pulse from Benzinga Newsdesk
May 07, 2024 | 11:39 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.